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ABSTRACT
Objective: This article investigates whether differences in utility scores
based on the EQ-5D and the SF-6D have impact on the incremental
cost–utility ratios in ﬁve distinct patient groups.
Methods: We used ﬁve empirical data sets of trial-based cost–utility studies
that included patients with different disease conditions and severity (mus-
culoskeletal disease, cardiovascular pulmonary disease, and psychological
disorders) to calculate differences in quality-adjusted life-years (QALYs)
based on EQ-5D and SF-6D utility scores. We compared incremental
QALYs, incremental cost–utility ratios, and the probability that the incre-
mental cost–utility ratio was acceptable within and across the data sets.
Results: We observed small differences in incremental QALYs, but large
differences in the incremental cost–utility ratios and in the probability that
these ratios were acceptable at a given threshold, in the majority of the
presented cost–utility analyses. More speciﬁcally, in the patient groups
with relatively mild health conditions the probability of acceptance of the
incremental cost–utility ratio was considerably larger when using the
EQ-5D to estimate utility. While in the patient groups with worse health
conditions the probability of acceptance of the incremental cost–utility
ratio was considerably larger when using the SF-6D to estimate utility.
Conclusions: Much of the appeal in using QALYs as measure of effective-
ness in economic evaluations is in the comparability across conditions and
interventions. The incomparability of the results of cost–utility analyses
using different instruments to estimate a single index value for health
severely undermines this aspect and reduces the credibility of the use of
incremental cost–utility ratios for decision-making.
Keywords: cost–utility, EQ-5D, SF-6D, utility.
Introduction
Instruments that estimate a single index value for health are
increasingly used to measure preferences for health states for the
estimation of quality-adjusted life-years (QALYs) in cost–utility
analyses. These measures are essentially generic health-related
quality of life instruments with pre-existing preference weights
that can be attached to each permutation of responses. Several
widely used instruments that estimate a single index value for
health are available, including the EQ-5D [1] and the SF-6D,
which uses responses to 11 of the questions on the SF-36 ques-
tionnaire [2]. These measures differ in terms of scoring algo-
rithm, and health state descriptive system, and as a result utility
scores may vary according to the choice of instrument [3,4].
Indeed, for a large range of clinical conditions there is evidence
for differences between the utility estimates of these two instru-
ments for a given patient [5–14]. Moreover, evidence suggests
there are differences in the level of agreement between the two
instruments over the range of ill health, potentially causing dif-
ferences in the estimated change in health state utility across
patient groups [3].
The EQ-5D and SF-6D scoring algorithms are derived using
different protocols using different valuation methods (time trade-
off and standard gamble, respectively). The literature suggests a
cross-over of standard gamble and time trade-off values: Stan-
dard gamble values are higher for more severe states, and the
opposite applies for the milder states [15]. It has indeed been
observed that for milder states the EQ-5D time trade-off utilities
were higher than the SF-6D standard gamble utilities [4]. This
may partly explain the narrower range of the SF-6D-derived
utilities as compared with EQ-5D-derived utilities, which may
indicate less sensitivity of the former. With regard to the descrip-
tive system, the operationalization of health in the two instru-
ments is not exactly the same: The “vitality” and “social
functioning” dimensions of the SF-6D are not explicitly included
in the EQ-5D. This would cause the SF-6D to be more sensitive
in situations when impact on these dimensions of health is
present. Also, the SF-6D dimensions have more levels than the
EQ-5D. Furthermore, because there is evidence for ﬂoor effects in
the SF-6D and ceiling effects in the EQ-5D, the instruments differ
in their description of “full health” and “worse health” [3,4,7].
As a result, the EQ-5D is thought to be sensitive in patient groups
with severe health state at baseline, but less sensitive in patient
groups with mild health states at baseline. The reverse would
apply to the SF-6D.
To our knowledge, two articles reported on the impact of the
choice of instrument on the incremental cost–utility ratio.
McDonough et al. [16] concluded, based on a review of the
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literature that across studies the EQ-5 D tended to provide more
favorable incremental cost–utility ratios than the SF-6 D. Grieve
et al. [17] showed that in the case of a model-based study of
antiviral therapy for patients with mild hepatitis using the SF-6D
rather than the EQ-5D resulted in more favorable incremental
cost–utility ratios. Nevertheless, of key concern is the fact
whether the differences in utility estimates have an impact on the
estimated impact of health-care interventions, and hence incre-
mental cost–utility ratios, because these are used in the appraisal
of a medical technology.
This article investigates whether the differences in utility
scores based on the EQ-5D and the SF-6D have impact on the
probability that the incremental cost–utility ratio is acceptable in
ﬁve distinct patient groups. This issue is addressed using ﬁve
empirical data sets of patients with different disease conditions
and different health state severity. By examining the impact of the
choice of instrument on whether the incremental cost–utility
ratios are acceptable across patient groups this study speciﬁcally
focuses on the difference in the description of “full health” and
“worse health” between the two instruments by examining ﬂoor
and ceiling effects. The article is structured as follows. We ﬁrst
introduce the data sources we used to investigate the impact of
the choice of EQ-5D or SF-6D utility estimates on the incremen-
tal cost–utility ratios. Next we describe the EQ-5D and SF-6D
instruments and the analyses we performed. In the results section
we compare within and across studies: baseline utility scores,
incremental QALYs, incremental cost–utility analyses, and the
uncertainty surrounding the incremental cost–utility ratios.
Methods
Data Sources
This research concerns secondary analyses of the data from ﬁve
separate studies conducted in The Netherlands, comprising in
total 794 patients. The studies concerned patients with car-
diovascular (hypertension), pulmonary (asthma), mental (panic
disorder), and musculoskeletal (ankylosing spondylitis and
osteoarthritis) disorders. All studies, except for the study with
osteoarthritis patients, were cost-effectiveness analyses con-
ducted alongside a randomized clinical trial. The osteoarthritis
study was designed as a historical comparison between two
matched patient groups. In all studies active treatments were
compared.
The study on hypertension concerned outpatients with hyper-
tension who were randomized to either home blood pressure
management, or continuance of ofﬁce blood pressure manage-
ment [18]. Measurements took place at baseline, 2, 4, 6, and 12
months. The patients with mild asthma (18 years or older, GINA
severity stages I to III) were randomized to a nurse-led telemoni-
toring intervention or care as usual [19]. In this study assess-
ments took place at baseline, and 4, 8, and 12 months. The group
of patients with active ankylosing spondylitis received a 3-week
course of spa treatment in a spa-resort either in Austria or in The
Netherlands, or continued usual care at home [20]. Quality of
life and cost data were collected at baseline, and 7, 12, 26, and 52
weeks later. The patients with panic disorder were treated with
sertraline or received usual care [21]. Measurements took place
at baseline, and 12 and 24 weeks later. Finally, patients with
osteoarthritis who underwent a total hip replacement either
received a joint recovery program or received care or usual [22].
Quality of life and costs were assessed at baseline, and 4 and 40
weeks later.
In each study both the EuroQol and the Medical Outcomes
Study 36-Item Short Form Health Survey (SF-36) were completed
at baseline and at each follow-up by the patients themselves.
From the data sources seven incremental cost–utility ratios could
be calculated: A. home blood pressure management versus care
as usual for hypertensive outpatients; B. nurse-led telemonitoring
versus care as usual for asthmatics; C. spa treatment in Austria
versus spa treatment in The Netherlands, and both spa treat-
ments versus care as usual for ankylosing spondylitis (D and E);
F. sertraline versus care as usual for panic disorder; and G. a joint
recovery program versus care as usual after hip replacement
surgery in osteoarthritis. Care as usual depends, of course, on the
speciﬁc disease treated and in each study reﬂected current care
for these patients in The Netherlands according to clinical guide-
lines if available.
Health-Related Quality of Life Measures
The EQ-5D instrument was developed by a European Group as
a standard nondisease-speciﬁc instrument for describing and
valuing quality of life [2]. It is a questionnaire with a descriptive
classiﬁcation system consisting of ﬁve dimensions (mobility, self-
care, usual activities, pain/discomfort, anxiety/depression), each
with three levels. The descriptive system allows for 243 discrete
health states. These health states are assigned values, using a
tariff based on the time trade-off. Several tariffs are available, but
for this study the original UK population tariff was applied in all
studies [23]. The EQ-5D utilities range from -0.59 to 1.00.
The SF-36 is a generic health status instrument, comprising
eight scales [24]. For the SF-6D, the items of the SF-36 are
converted into a six-dimensional health state classiﬁcation
system, with between two and six levels. This yields 18,000
different health states. The health states are assigned preference
weights derived from valuations of a sample of 249 SF-6D health
states using the standard gamble in a representative sample of the
UK population [25]. The SF-6D utilities range from 0.29 to 1.00.
See Supporting information for the scoring algorithms used to
calculate utilities from the data sets in this study at: http://
www.ispor.org/Publications/value/ViHsupplementary/ViH13i2_
Joore.asp
Data Analyses
For this study only patients who completed both the SF-36 and
the EQ-5D at baseline were included in the analysis. Floor and
ceiling effects in the baseline utility scores were investigated by
computing the proportion of patients at the lowest and highest
possible utility score. For each patient two outcomes in QALYs
were calculated: one based on the EQ-5D utility scores and the
other based on the SF-6D utility scores. The patient-level QALYs
were estimated by applying the area-under-the-curve method,
thus assuming linear change between the discrete follow-up
points in time [26]. See Supporting information for details on the
QALY calculation at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i2_Joore.asp
The time horizon was the study duration. To obtain the
incremental QALYs in each study multiple regression analysis
was applied to control for differences in baseline utility between
the study arms [27]. All analyses were performed using SPSS,
version 16.0.
For each study two incremental cost–utility ratios were cal-
culated by dividing the difference in costs between the two alter-
natives by the difference in both QALYs. To get insight in the
uncertainty around the incremental cost-effectiveness ratios non-
parametric bootstrap simulations were conducted [28]. In the
bootstrap simulations a sample of “costs,” “QALY based on
EQ-5D,” and “QALY based on SF-6D” trios of equal size of the
original sample was selected a thousand times with replacement.
From these data 95% uncertainty intervals for the differences in
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both QALYs were calculated based on the 2.5th and the 97.5th
percentile. The difference in the joint distribution of the incre-
mental results is shown in cost-effectiveness planes (CE plane).
The difference in decision uncertainty is presented in cost-
effectiveness acceptability curves [29]. Cost-effectiveness accept-
ability curves present uncertainty as the probability that an
intervention has the greatest net beneﬁt as a function of the
willingness to pay (WTP) for a certain effect (in our case a
QALY). The probability that one intervention is preferred over
the other is represented graphically in the CE planes as the
proportion of the joint density (DC, DE) to the lower right of a
WTP line. A WTP line is a straight line through the origin of the
CE plane that connects points with equal WTP values. This
proportion can be estimated repeatedly while rotating the WTP
line counter clockwise from horizontal (i.e., WTP = 0) to vertical
(i.e., WTP = inﬁnite). Hence, the shape of the cost-effectiveness
acceptability curve is dependent upon the location of the joint
density (DC, DE) within the CE plane.
Results
Patient Characteristics
In total 583 patients were included in the analyses in the under-
lying study. The characteristics of the patients included in the ﬁve
data sets that were considered for this comparative study are
shown in Table 1. At baseline, the ranking of the utility scores
was the same for the EQ-5D and the SF-6D. The highest utility
scores were observed in the hypertension data set (0.842 and
0.773, respectively), and the lowest in the osteoarthritis data set
(0.339 and 0.584, respectively). The EQ-5D utility scores were
higher than the SF-6D utility scores in the data sets with a
relatively high utility score (hypertension, asthma) and lower in
the data sets with a relatively low utility score (osteoarthritis).
Floor effects were not observed. Ceiling effects were mostly
found in the hypertension and asthma data sets, and more preva-
lent in the EQ-5D than in the SF-6D utility scores. Across the
data sets, at baseline the range of EQ-5D utility scores (0.503)
was 2.7 times larger than the range of SF-6D utility scores
(0.189). Also, the standard deviations of the utility scores at
baseline were larger for the EQ-5D utility scores.
Incremental QALYs
The incremental EQ-5D QALY varied from minus 0.011 (the
equivalent of 4 days in perfect health lost; osteoarthritis) to
0.055 (the equivalent of 20 days in perfect health gained, spa
treatment in Austria versus in The Netherlands for ankylosing
spondylitis). For the SF-6D the incremental QALYs varied from
minus 0.012 (4 days lost, asthma) to 0.031 (11 days gained, spa
treatment in Austria vs. care as usual for ankylosing spondyli-
tis). The 2.5th to 97.5th percentile conﬁdence intervals sur-
rounding the incremental QALYs all included zero, except for
the EQ-5D incremental QALY in the asthma and Spa Austria
versus care as usual data sets.
The incremental beneﬁt from the new intervention was larger
for EQ-5D QALYs than for SF-6D QALYs in the hypertension
and asthma data sets. The same was found in the in ankylosing
spondylitis data set for the comparison of the Spa treatment in
Austria with care as usual and with the Spa treatment in The
Netherlands. The largest difference in incremental QALY
between the EQ-5D and SF-6D was observed in the asthma data
set: 0.045 QALY difference (16 days). The conﬁdence intervals
for the EQ-5D incremental QALY were all larger than for the
SF-6D incremental QALY. Ta
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Incremental Cost–Utility Analyses
The point estimates of the incremental cost–utility ratios indi-
cated dominance in the comparison of the two spa treatments for
ankylosing spondylitis, irrespective of the utility instrument used.
The cost–utility ratios in the hypertension, asthma, and ankylos-
ing spondylitis (spa treatment in Austria vs. usual care) data sets
were more acceptable when based on EQ-5D utility. The ratios in
the panic disorder, osteoarthritis, and ankylosing spondylitis (spa
treatment in The Netherlands vs. usual care) data sets were lower
when based on SF-6D utility. The incremental costs, QALYs, and
cost–utility ratios are presented in Table 2, ranked from the data
set with the highest baseline utility score (A: hypertension) to the
data set with the lowest baseline utility score (G: osteoarthritis).
On the CE planes (Fig. 1) it is shown that the uncertainty
surrounding the point estimates of the incremental cost–utility
ratios in all seven comparisons was larger if the QALY is based
on EQ-5D utility. The difference in the probability of acceptance
of cost-effectiveness between the EQ-5D and SF-6D is shown in
the acceptability curves (Fig. 2: The comparisons are ranked
from higher [A] to lower [G] baseline utility score). In Figure 1A,
B, F and G the joint density (DC, DE) is, partly, in the southwest
quadrant, indicating less costly and less effective. Therefore, if
the WTP increases, more of the joint distribution will fall above
the WTP line, and the probability of acceptance decreases. There-
fore the cost-effectiveness acceptability curves in Figure 2A, B, F
and G are falling. For ceiling ratios between €0 and €80,000 per
QALY the smallest differences between EQ-5D- and SF-6D-
derived cost per QALY were observed in the ankylosing spondyli-
tis data. The largest differences were observed in the asthma and
panic disorder data (Fig. 2B and F). At a ceiling ratio of €40.000
per QALY the probability of acceptance of nurse-led telemoni-
toring for asthma was 0.55 larger when using EQ-5D utility
estimates to calculate QALYs (Fig. 2B). In the panic disorder data
set it is the other way around. At €40,000 per QALY the prob-
ability of accepting sertraline was 0.45 larger when using SF-6D
utility estimates to calculate QALYs (Fig. 2F). By “reading”
Figure 2 from left to right and from top to bottom, it is shown
that ﬁrst (higher baseline utility scores; A, B) the probability that
the intervention is cost-effective is higher based on the EQ-5D,
while later (lower baseline utility scores; F, G) the probability is
higher when based on SF-6D utility scores.
Discussion and Conclusions
We investigated the impact of the differences in utility scores
based on the EQ-5D and the SF-6D on the probability that
incremental cost–utility ratios were acceptable, in ﬁve distinct
patient groups. Our main ﬁndings are the following. First,
EQ-5D utility scores were higher than SF-6D utility scores for
disease states with higher baseline utility scores and lower for
states with lower baseline utility scores. This is in line with
previous evidence: Healthier individuals tend to have higher
mean scores on the EQ-5D, and less healthy individuals tend to
have higher scores on the SF-6D [30]. Also, the considerable
ceiling effects observed in the EQ-5D utility scores in the data sets
with relatively mild conditions (hypertension, asthma) are in line
with the literature [7]. Floor effects were not observed. Second,
the observed differences in incremental QALY were very small,
and mainly occurred in the trials with baseline utility scores at
either end of the health spectrum. The EQ-5D provided more
favorable incremental cost–utility ratios for data sets with higher
baseline utility and the opposite in the data sets with lower
baseline utility. In light of the observed ceiling effects, which are
expected to decrease sensitivity to change, in mainly the data sets Ta
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with higher baseline utility, this ﬁnding seems somewhat coun-
terintuitive. Third, the uncertainty surrounding the incremental
cost–utility ratios was larger when using EQ-5D utility scores in
each data set. This is not surprising, taking into account the
considerably larger standard deviation of EQ-5D utility scores.
Fourth, the probability that the incremental cost–utility ratios
were acceptable was considerably larger when using EQ-5D
utility scores in the data sets with higher baseline utility scores;
although the opposite was found in the data sets with lower
baseline utility scores.
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Figure 1 Distribution of incremental cost–utility results based on EQ-5D and SF-6D quality-adjusted life-year (QALY) estimates for each comparison ranked from
higher (A) to lower (G) baseline utility score (€/QALY). (A) Hypertension trial; (B) asthma trial; (C) ankylosing spondylitis trial (spa Austria versus spa The
Netherlands); (D) ankylosing spondylitis trial (spa Austria vs. care as usual); (E) ankylosing spondylitis trial (spa The Netherlands vs. care as usual); (F) panic disorder
trial; (G) osteoarthritis of the hip trial.
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Addressing our main question: Even though the differences in
incremental QALYs were rather small, the choice of instrument
had considerable impact on the probability that incremental
cost–utility ratios are acceptable. Moreover, across the patient
groups and comparisons we included in this study, we found that
the cost–utility ratios were more acceptable when using EQ-5D
in relatively mild health conditions and using SF-6D in relatively
serious health conditions. This result does not conﬁrm the ﬁnd-
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Figure 2 Cost-effectiveness acceptability curves based on EQ-5D and SF-6D quality-adjusted life-year (QALY) estimates for each comparison, ranked from higher
(A) to lower (G) baseline utility score. (A) Hypertension trial; (B) asthma trial; (C) ankylosing spondylitis trial (spa Austria vs. spa The Netherlands); (D) ankylosing
spondylitis trial (spa Austria vs. care as usual); (E) ankylosing spondylitis trial (spa The Netherlands vs. care as usual); (F) panic disorder trial; (G) osteoarthritis of the
hip trial.
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ings of McDonough et al. [16], who concluded, based on a
review of the literature, that across studies the EQ-5D tended to
provide more favorable incremental cost–utility ratios. This
result also is not in line with the expectation that the ceiling
effects in the EQ-5D would lead to more favorable EQ-5D results
in severe conditions.
The data sets we used reﬂect a considerable severity range and
very different areas in health: musculoskeletal disease, cardiovas-
cular pulmonary disease, and psychological disorders. Neverthe-
less, it certainly was a convenience sample of studies as available
in our department. The systematic difference of the choice for
EQ-5D or SF-6D on whether incremental cost–utility ratios are
acceptable we observed can be a result of the speciﬁc sample of
studies we used. For instance, we did not observe ﬂoor effects in
the SF-6D, although others did [3,31–32]. This may be the
reason why in the data set with a relatively serious condition
(osteoarthritis), somewhat counter intuitively, the SF-6D utility
scores translated into a larger probability that the intervention
was cost-effective. If ﬂoor effects would be present in the SF-6D
baseline utility scores, this result could be reversed. In addition,
in the data sets we used only small differences in QALYs were
observed between the interventions. Although this is a rather
common ﬁnding when comparing a new intervention with the
best available alternative, it would favor the instrument that
overall is more sensitive to change. Taking into account the
differences in health state description and scoring algorithm
between the EQ-5D and SF-6D it is not clear which instrument
would overall be more sensitive to change. It is expected that this
will differ between patient groups and interventions.
The ﬁndings of this study suggest that besides the differences
in the deﬁnition of worse and full health, other sources of differ-
ences in change in utility score as measured with EQ-5D and the
SF-6D play a role. Therefore, it is of great importance that we
further improve our understanding of the impact of the choice of
the utility instrument on the probability that an incremental
cost–utility ratio is acceptable. If feasible, we like to recommend
the use of more than one utility instrument in trial-based eco-
nomic evaluations to obtain as much comparative data as pos-
sible. In addition, we strongly encourage researchers to publish
any available cost-effectiveness data in which two or more instru-
ments are used to estimate a single index value for health. More
explicitly, because in this area the burden of evidence arises from
a series of analyses and not a single study, repeating our analyses
for other conditions and interventions with a different type and
magnitude of effect seems worthwhile. In addition, other sources
of differences between the instruments need to be investigated.
For instance the differences in domain structure may have impact
on utility change. Furthermore, differences in utility change may
arise from differences in the interval properties of the utility
scales of the EQ-5D and SF-6D.
In conclusion, we observed small differences in incremental
QALYs, but remarkably large differences in the probability that
the incremental cost–utility ratio is acceptable in the majority of
the presented cost–utility analyses. More speciﬁcally, in the
patient groups with relatively mild health conditions the prob-
ability of acceptance of the incremental cost–utility ratio was
considerably larger when using the EQ-5D to estimate utility.
While in the patient groups with relatively serious health condi-
tions the probability of acceptance of the incremental cost–utility
ratio was considerably larger when using the SF-6D to estimate
utility. A systematic difference in the probability of accepting the
cost–utility of interventions as a result of the choice of utility
instrument would seriously bias the comparability of the results
of economic evaluations. This is problematic, because much of
the appeal in using QALYs as measure of effectiveness in eco-
nomic evaluations is in the comparability across conditions and
interventions. The incomparability of the results of cost–utility
analyses using different utility instruments reduces the credibility
of the use of incremental cost–utility ratios for decision-making.
An earlier version of this work was presented at the International
Health Economics Association Conference, July 2007, Copen-
hagen, Denmark. Two anonymous reviewers are kindly acknowl-
edged for their valuable comments.
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